Clinical Features and Survival of TFE3-Rearranged Renal Cell Carcinoma vs Clear Cell RCC

Overview

This retrospective study compared clinical characteristics and survival outcomes of TFE3-rearranged renal cell carcinoma (TFE3-rRCC) with clear cell RCC (ccRCC) using propensity score matching. TFE3-rRCC patients were younger, more often female, and had distinct pathological features. Survival analyses suggested comparable overall and progression-free survival between matched TFE3-rRCC and ccRCC cohorts, supporting partial nephrectomy as a feasible treatment for localized TFE3-rRCC.

Background

TFE3-rRCC is a rare subtype of renal cell carcinoma characterized by chromosomal rearrangements involving the TFE3 gene. It accounts for a significant proportion of pediatric RCCs and a small fraction of adult RCCs. Diagnosis is challenging due to heterogeneous morphology and overlapping immunophenotypes, with FISH testing being the gold standard for confirmation. Clinical behavior varies, with some reports indicating aggressive disease and others showing outcomes similar to ccRCC, especially in early-stage disease.

Data Highlights

Key Findings

• TFE3-rRCC patients were younger (median 33 years) and predominantly female (61.3%).
• Most TFE3-rRCC cases were asymptomatic at diagnosis (61.3%).
• Pathological staging showed 40.3% T1a tumors and 17.7% had nodal involvement (pN1).
• Partial nephrectomy was performed in 43.5% of TFE3-rRCC patients, mostly in T1a tumors.
• Propensity score matching minimized confounding when comparing TFE3-rRCC to ccRCC.
• Survival outcomes (overall and progression-free) were comparable between matched TFE3-rRCC and ccRCC cohorts, supporting oncologic safety of nephron-sparing surgery in localized TFE3-rRCC.

Clinical Implications

Clinicians should consider TFE3-rRCC in younger patients, especially females, presenting with renal masses. Accurate diagnosis requires FISH confirmation due to morphological and immunohistochemical overlap with other RCC subtypes. Partial nephrectomy appears to be a safe and effective surgical option for localized TFE3-rRCC, similar to ccRCC, facilitating nephron preservation without compromising oncologic outcomes.

Conclusion

TFE3-rRCC exhibits distinct demographic and pathological features but demonstrates survival outcomes comparable to ccRCC when matched for clinical factors. Partial nephrectomy is a feasible treatment for localized TFE3-rRCC, supporting nephron-sparing approaches in this rare RCC subtype.

References

1. WHO Classification of Tumors Editorial Board 2022 -- WHO Classification of Tumors: Urinary and Male Genital Tumors
2. Argani et al. 2007 -- Xp11 Translocation Renal Cell Carcinoma
3. Klatte et al. 2012 -- Clinical and Pathologic Features of TFE3-Rearranged RCC